Back to Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 2

Docetaxel for the post-surgery treatment of patients with node-positive breast cancer

Authors Pant S, Chilukuri MP, Ramaswamy B

Published 11 April 2008 Volume 2008:4(2) Pages 419—424


Shubham Pant1, Meena P Chilukuri2, Bhuvaneswari Ramaswamy1

1Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Ohio State University, Columbus, Ohio, USA; 2Mount Carmel Medical center, Columbus, Ohio

Abstract: Adjuvant chemotherapy reduces risk of relapse and cancer-related mortality in early stage breast cancer. Over the last decade, taxanes (paclitaxel and docetaxel) have been incorporated into various adjuvant trials and have demonstrated a significant benefit in the management of early stage breast cancer. Clinical trials using combinations of taxanes with targeted therapy have also shown considerable activity in breast cancer. This article reviews the pharmacology of docetaxel, a semi-synthetic taxane, and the clinical trials supporting its use in patients with node-positive breast cancer.

Keywords: docetaxel, node-positive breast cancer, post-surgery treatment, taxanes

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 


Other article by this author:

Ixabepilone as monotherapy or in combination for the treatment of advanced breast cancer

Erin M Bertino, Bhuvaneswari Ramaswamy

Breast Cancer: Targets and Therapy 2010, 2:13-23

Published Date: 24 May 2010

Readers of this article also read:

Self-assembling surfactant-like peptide A6K as potential delivery system for hydrophobic drugs

Chen Y, Tang C, Zhang J, Gong M, Su B, Qiu F

International Journal of Nanomedicine 2015, 10:847-858

Published Date: 23 January 2015

The concept of control of COPD in clinical practice

Soler-Cataluña JJ, Alcázar-Navarrete B, Miravitlles M

International Journal of Chronic Obstructive Pulmonary Disease 2014, 9:1397-1405

Published Date: 12 December 2014

Engineered hepatitis B virus surface antigen L protein particles for in vivo active targeting of splenic dendritic cells

Matsuo H, Yoshimoto N, Iijima M, Niimi T, Jung J, Jeong SY, Choi EK, Sewaki T, Arakawa T, Kuroda S

International Journal of Nanomedicine 2012, 7:3341-3350

Published Date: 3 July 2012

Infantile hemangiomas: from pathogenesis to clinical features

Rosenblatt A, Mathes EF, Rosbe KW

Research and Reports in Neonatology 2012, 2:55-64

Published Date: 29 June 2012

Lift the quilt in case of atrial fibrillation and disc prolapse

Bastovansky A, Ziegler K, Stöllberger C, Finsterer J

Vascular Health and Risk Management 2012, 8:389-392

Published Date: 22 June 2012

Effect of dispersants of multi-walled carbon nanotubes on cellular uptake and biological responses

Haniu H, Saito N, Matsuda Y, Kim YA, Park KC, Tsukahara T, Usui Y, Aoki K, Shimizu M, Ogihara N, Hara K, Takanashi S, Okamoto M, Ishigaki N, Nakamura K, Kato H

International Journal of Nanomedicine 2011, 6:3295-3307

Published Date: 9 December 2011

Sub-Tenon′s triamcinolone for post-partum Purtscher′s-like retinopathy

Jeffrey Olson, Behnaz Rouhani, Naresh Mandava

Clinical Ophthalmology 2008, 2:195-198

Published Date: 7 March 2008

Dalbavancin in the treatment of complicated skin and soft-tissue infections: a review

Jason W Bennett, James S Lewis II, Michael W Ellis

Therapeutics and Clinical Risk Management 2008, 4:31-40

Published Date: 8 February 2008


Vascular Health and Risk Management 2006, 2:515-515

Published Date: 15 December 2006